Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage

Antiviral Research

Volumn 116, Issue , 2015, Pages 45-47

  Boglione, Lucio ^a   Cusato, Jessica ^a   Cariti, Giuseppe ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Fibrosis stage; Genotype 1; HCV; IL28B; RVR; Standard therapy

Indexed keywords

INTERLEUKIN 28B; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C GENOTYPE 1 INFECTION; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922692767     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.01.014     Document Type: Article

References (13)

1. A. Andriulli, V. Di Marco, M. Margaglione, A.M. Ippolito, G. Fattovich, A. Smedile, M.R. Valvano, V. Calvaruso, D. Gioffreda, M. Milella, F. Morisco, M. Felder, G. Brancaccio, M. Fasano, P. Gatti, P. Tundo, M. Barone, R. Cozzolongo, M. Angelico, G. D'Andrea, N. Andriulli, M.L. Abate, G. Mazzella, G.B. Gaeta, A. Craxi, and T. Santantonio Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin J. Hepatol. 60 2014 16 21
2. L. Boglione, J. Cusato, A. De Nicolo, G. Cariti, S. Allegra, V. Ghisetti, G. Di Perri, and A. D'Avolio Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms Antiviral Res. 106 2014 105 110
3. L. Boglione, A. De Nicolo, G. Di Perri, and A. D'Avolio Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools J. Hepatol. 61 2014 178 179
4. A. D'Avolio, A. Ciancio, M. Siccardi, L. Baietto, M. Simiele, G. Cariti, A. Calcagno, A. Smedile, J. Cusato, S. Bonora, M. Rizzetto, and G. Di Perri Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4 Hepatology 54 2011 2279
5. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, M. Simiele, J. Cusato, L. Baietto, D.A. Marucco, G. Cariti, A. Calcagno, D.G. de Requena, M. Sciandra, G. Troshina, G.P. Caviglia, S. Bonora, M. Rizzetto, and G. Di Perri Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment Ther. Drug Monit. 34 2012 722 728
6. EASL EASL recommendations on treatment of hepatitis C 2014 J. Hepatol. 61 2014 373 395
7. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
8. T.L. Kieffer, and S. George Resistance to hepatitis C virus protease inhibitors Curr. Opin. Virol. 8C 2014 16 21
9. Y. Luo, C. Jin, Z. Ling, X. Mou, Q. Zhang, and C. Xiang Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis Gene 513 2012 292 296
10. C. Park, S. Jiang, and K.A. Lawson Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis J. Clin. Pharm. Ther. 39 2014 14 24
11. M.L. Shiffman, and Y. Benhamou Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Liver Int. 33 Suppl. 1 2013 105 110
12. M.L. Shiffman, and R. Esteban Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver Int. 32 Suppl. 1 2012 54 60
13. A.F. Stattermayer, R. Stauber, H. Hofer, K. Rutter, S. Beinhardt, T.M. Scherzer, K. Zinober, C. Datz, A. Maieron, E. Dulic-Lakovic, H.H. Kessler, P. Steindl-Munda, M. Strasser, C. Krall, and P. Ferenci Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C Clin. Gastroenterol. Hepatol. 9 344-350 2011 e342